-

EPAM Investigation Announcement: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of EPAM Systems, Inc. (NYSE: EPAM) Investors

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of EPAM Systems, Inc. (NYSE: EPAM) (“EPAM”).

On June 5, 2023, EPAM lowered its expectations for the second quarter and the full year, claiming that the demand for IT consulting appears to have dried up. This shocked the market as the company just made its prior guidance on its first quarter earnings call only one month ago on May 5, 2023. Following this news, shares of EPAM common stock plunged more than 20%.

If you are an EPAM Systems, Inc. investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/epam-systems-inc-investigation?utm_source=PR&utm_medium=link&utm_campaign=epam&mktm=r

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

Kessler Topaz Meltzer & Check, LLP

NYSE:EPAM

Release Versions
$Cashtags

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

More News From Kessler Topaz Meltzer & Check, LLP

KD Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 13, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyndryl Holdings, Inc.

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. (Kyndryl) (NYSE: KD) on behalf of those who purchased or acquired Kyndryl securities between August 7, 2024, and February 9, 2026, inclusive. The lawsuit is filed in the United States District Court for the Eastern District of New York and is captioned Brander v. Kyndryl Holdings, Inc., et al, Case No. 1:...

uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). This action, captioned Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the United States District Court for...

RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: RARE) on behalf of those who purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Bailey v. Ultragenyx Pharmace...
Back to Newsroom